



Net income declined in Q3-24 as a result of gross profit margin contraction and previous comparable periods' one-off reversals, while reaching its highest revenue to date

Care reported a net income of SAR 60.2mn in Q3-24 (down 18.0% Y/Y, and 13.4% Q/Q) due to gross margin contraction; while previous comparable results were supported by zakat and ECL reversals. Bottom line results came in 13.7% lower than our estimates of SAR 69.7mn, and 15.8% lower from the market's. This quarter, however, saw the highest revenue recorded for Care to date at SAR 325.8mn, supported by client mixes as well as a 12% increase in outpatient visits (Y/Y). Gross profit margins, however recorded their lowest (TTM) at 34.2% while still up 90bps Y/Y (down 220 bps Q/Q) as a result of the consumables required for the case mix for the quarter. The deviation in GPM from our estimates (200bps below our forecasted 36.2%) drove the bulk of the deviation in our estimates; while OPEX to revenues at 12.5% (down 200bps Q/Q and up c. 640bps Y/Y) further displayed a normalized result in absence of Q3-23's ECL reversal. Going forward, we expect the class C AlSalam acquisition in Riyadh to continue to pressure GPMs, while driving top line growth in the short term, along with the effects of the Prince Sultan Medical City contract and the Haram facility ramp up. We maintain our "Neutral" recommendation on the stock with a **TP of SAR 202.0** per share.

- Care reported a net income of SAR 60.2mn (down 18.0% Y/Y, and 13.4% Q/Q) mainly driven by GPM contractions; results also came at a decline partially as a result of non-reoccurring incomes in the comparable periods (net SAR 8.4mn ECL income due to a reversal in Q3-23, and a net-positive SAR 4.4mn zakat contribution in Q2-24). Higher financing cost, and lesser finance income as a result decreased deposits weighed in on bottom line results for the quarter. Operationally, GPMs pressured results to reach SAR 60.2mn, deviating negatively from our estimates of SAR 69.7mn by 13.7% and 15.8% from the market's SAR 71.5mn.
- Revenue reached its highest recorded to date at SAR 325.8mn (up 18.3% Y/Y and 9.8% Q/Q) driven by favorable client mixes and the support of the openings of AlBalad and Haram facilities. Revenues were in line with our estimates of SAR 331.7mn at a 1.8% deviation. Outpatient visits grew c. 12%, while inpatient revenues remained relatively flat Y/Y at c. -1%. Inpatient volume growths, however, are improving sequentially in the last three quarters after the completion of the National Guard Contract in Q2-23 which previously provided a higher comparable base. Occupancy reached 66.8% across all facilities for 9M-24.
- Gross profits came in at SAR 111.5mn (7.1% lower than our estimated SAR 120.1mn); as GP margins for the quarter reached 34.2% (up 90bps Y/Y, and down 220bps Q/Q), declining Q/Q as a result of consumables related to the quarter's case mix. At a 200bps deviation from our estimated 36.2%. Notable increases in cost of sales were in Salaries and Benefits, up c. 23% Y/Y as AlBalad and Haram facilities came in since then.
- Operating income, reported at SAR 70.9mn (against our estimate of SAR 79.0mn), came in 5.4% lower Y/Y as a result of ECL reversals in the previous period, and up 8.8% Q/Q. OPEX to revenues then reached 12.5%, down 200bps Q/Q and up c. 640bps Y/Y, as Q3-23 was supported by the ECL reversal netting a positive SAR 8.4mn income from provisions; while this quarter saw higher provisions for insurance clients expected to be reversed at later periods. OPEX to Revenues were in line with our estimate of 12.38%.

AJC view and valuation: Care's Q3-24 results displayed healthy top line growth driven by new facilities and growth in outpatient visits. Net income, however, was absent from comparable periods' reversals which pressured bottom line growth. Reported GP margins drove the deviation from our results, while OPEX-to-revenues came in in line with results. We expect GPM margins to continue being pressured in the immediate term while Hamra and Mental Health Facilities ramp up, and ahead of the class C facility consolidation. Going forward, we expect the Salam acquisition (visible in Q4-24), Prince Sultan Medical City contract, and the Haram facility ramp up to drive short term performance; while the Narjis expansion at 400 beds (rolled out gradually and estimated live by 2028) to drive longer term performance. We forecast net income for FY24 & FY25 at SAR 310.1mn and SAR 340.8mn, respectively (growing 28.7% and 9.9% respectively). Standing at a forward PE of 24.2x (FY25E). We maintain our **TP of SAR 202.0** per share, at a "Neutral" recommendation.

Results Summary

| SAR mn | Q3-23 | Q2-24 | Q3-24 | Change Y/Y | Change Q/Q | Deviation from AJC Estimates |
|---------------------|--------------|--------------|--------------|---------------|---------------|------------------------------|
| Revenue | 275.4 | 296.8 | 325.8 | 18.3% | 9.8% | -1.8% |
| Gross Profit | 91.8 | 108.2 | 111.5 | 21.5% | 3.1% | -7.1% |
| Gross Margin | 33.3% | 36.4% | 34.2% | - | - | - |
| EBIT | 74.9 | 65.1 | 70.9 | -5.4% | 8.8% | -10.3% |
| Net Profit | 73.4 | 69.5 | 60.2 | -18.0% | -13.4% | -13.7% |
| EPS | 1.64 | 1.55 | 1.34 | - | - | - |

Source: Company Reports, Aljazira Capital

| | |
|-----------------------------|----------------|
| Recommendation | Neutral |
| Target Price (SAR) | 202.0 |
| Upside / (Downside)* | 9.8% |

Source: Tadawul *prices as of 21st of Oct 2024

Key Financials

| SARmn (unless specified) | FY22 | FY23 | FY24E | FY25E |
|--------------------------|-------|-------|-------|-------|
| Revenues | 918 | 1,082 | 1,282 | 1,511 |
| Growth % | 8.6% | 17.8% | 18.5% | 17.8% |
| Net Income | 170.1 | 240.9 | 310.1 | 340.8 |
| Growth % | 24.7% | 41.7% | 28.7% | 9.9% |
| EPS | 3.79 | 5.37 | 6.91 | 7.60 |
| DPS | 1.00 | 2.00 | 2.25 | 2.50 |

Source: Company reports, Aljazira Capital

Key Ratios

| | FY22 | FY23 | FY24E | FY25E |
|----------------|-------|-------|--------|-------|
| Gross Margin | 31.6% | 34.2% | 36.3% | 35.5% |
| OP Margin | 20.6% | 22.8% | 23.6% | 24.3% |
| Net Margin | 18.5% | 22.3% | 24.2% | 22.6% |
| EBITDA Margin | 25.1% | 26.9% | 27.27% | 28.8% |
| RoE | 12.6% | 14.2% | 17.7% | 19.9% |
| P/E | 19.5 | 32.5 | 26.6 | 24.2 |
| P/B | 2.6 | 5.4 | 5.0 | 4.4 |
| EV/EBITDA | 13.3 | 26.8 | 23.6 | 19.1 |
| Dividend Yield | 1.4% | 1.1% | 1.2% | 1.4% |


Source: Company reports, Aljazira Capital

Key Market Data

| | |
|------------------------|-------------|
| Market Cap(bn) | 8.0 |
| YTD% | 8.95% |
| 52 week (High)/(Low) | 227.6/120.0 |
| Share Outstanding (bn) | 44.85 |

Source: Company reports, Aljazira Capital

Price Performance



Source: Tadawul, Aljazira Capital

Equity Analyst

Ibrahim Elaiwat

+966 11 2256115

i.elaiwat@Aljaziracapital.com.sa





RESEARCH DIVISION

Head of Sell-Side Research - AGM
Jassim Al-Jubran
+966 11 2256248
j.aljabran@aljaziracapital.com.sa

RESEARCH
DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING
TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068